2025
Consensus guideline for the management of colorectal cancer with peritoneal metastases
Schultz K, Bansal V, Wach M, Bhutiani N, Godley F, Wang J, Waheed M, Buchheit J, Papai E, Campbell S, Schleimer L, Su D, Turaga K, Gunderson C, White M, Uppal A, Raghav K, Labow D, Sarpel U, Shergill A, Shen J, Eng C, Foote M, Baumgartner J, Group P. Consensus guideline for the management of colorectal cancer with peritoneal metastases. Cancer 2025, 131: e35869. PMID: 40558054, DOI: 10.1002/cncr.35869.Peer-Reviewed Original ResearchMeSH KeywordsColorectal NeoplasmsConsensusCytoreduction Surgical ProceduresDelphi TechniqueHumansPeritoneal NeoplasmsPractice Guidelines as TopicConceptsManagement of colorectal cancerCRC-PMColorectal cancerPeritoneal metastasisConsensus guidelinesPeritoneal surface malignancy centersCirculating tumor DNA testingUpfront cytoreductive surgerySite of metastasisProspective multicenter trialOptimal treatment strategyAssess agreement levelsLevel of evidenceOverall level of evidenceClinical management pathwaysModified Delphi techniqueCytoreductive surgerySystemic therapyMulticenter trialRisk stratificationTreatment strategiesPathway blockWeak recommendationPathological featuresMetastasisNeuronal ALKAL2 and its ALK receptor contribute to the development of colitis-associated colorectal cancer
Delanne-Cuménal M, Defaye M, Delanne-Cuménal A, Ahmed M, Ho V, Abdullah N, Alhassoun M, Svendsen K, Mager L, Schlessinger J, Hirota S, Altier C. Neuronal ALKAL2 and its ALK receptor contribute to the development of colitis-associated colorectal cancer. Proceedings Of The National Academy Of Sciences Of The United States Of America 2025, 122: e2500632122. PMID: 40493183, PMCID: PMC12184428, DOI: 10.1073/pnas.2500632122.Peer-Reviewed Original ResearchConceptsColitis-associated colorectal cancerAnaplastic lymphoma kinaseColorectal cancerAnaplastic lymphoma kinase activityColitis-associated colorectal cancer progressionAnaplastic lymphoma kinase receptorTRPV1+ nociceptorsDevelopment of colitis-associated colorectal cancerMouse colonic organoidsALK signalingInflammatory painTumor burdenTreatment resistanceSensory neuronsTumor growthColonic organoidsALKAL2Colonic mucosaOverall inflammationCancer progressionCancerIn vivoTRPV1NeuronsInflammationIndole-3-lactic acid suppresses colorectal cancer via metabolic reprogramming
Zhou S, Wang K, Huang J, Xu Z, Yuan Q, Liu L, Wang Z, Miao J, Wang H, Wang T, Guan W, Ding C. Indole-3-lactic acid suppresses colorectal cancer via metabolic reprogramming. Gut Microbes 2025, 17: 2508949. PMID: 40409349, PMCID: PMC12118437, DOI: 10.1080/19490976.2025.2508949.Peer-Reviewed Original ResearchConceptsIndole-3-lactic acidColorectal cancer patientsColorectal cancerAryl hydrocarbon receptorDownregulated glucose metabolismPotential clinical therapeutic targetsAnti-apoptotic capabilityInfluence tumor progressionGut microbiota metabolismTumor cell proliferationMetagenomic sequencingPhosphorylation sitesXenograft mouse modelGut microbiotaClinical therapeutic targetMetabolic reprogrammingMicrobiota metabolismP-STAT3Tumor progressionTumor malignancyMouse modelTryptophan metabolismCancer cellsIn vitro experimentsCRC developmentMitochondrial gene SLC25A24 regulated anti-tumor immunity and inhibited the proliferation and metastasis of colorectal cancer by PKG1-dependent cGMP/PKG1 pathway
Gao Y, Peng Y, Zhou Y, Zhu J, Fu S, Chen Y, Cai C, Han Y, Shen H, Zeng S, Mao L, Xiao Z. Mitochondrial gene SLC25A24 regulated anti-tumor immunity and inhibited the proliferation and metastasis of colorectal cancer by PKG1-dependent cGMP/PKG1 pathway. International Immunopharmacology 2025, 157: 114664. PMID: 40334626, DOI: 10.1016/j.intimp.2025.114664.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsAnti-tumor immunityColorectal cancerResponse to immune checkpoint inhibitorsAssociated with worse overall survivalKaplan-Meier survival analysisProgression-free survivalTumor immune regulationMetastasis of colorectal cancerMitochondrial solute carriersMicrosatellite instabilityColorectal cancer cell linesColorectal cancer patientsCancer-related mortalityProliferation-related markersCheckpoint inhibitorsColorectal cancer progressionOverall survivalImmune infiltrationPotential therapeutic targetPrognostic markerUnfavorable prognosisColorectal cancer tissuesImmune regulationClinical cohortUnveiling fine-scale spatial structures and amplifying gene expression signals in ultra-large ST slices with HERGAST
Gong Y, Yuan X, Jiao Q, Yu Z. Unveiling fine-scale spatial structures and amplifying gene expression signals in ultra-large ST slices with HERGAST. Nature Communications 2025, 16: 3977. PMID: 40295488, PMCID: PMC12037780, DOI: 10.1038/s41467-025-59139-w.Peer-Reviewed Original ResearchConceptsGene expression signalsSpatial transcriptomics data analysisExpression signalsTranscriptome data analysisHeterogeneous graph networkReal-world datasetsSpatial expression patternsOver-smoothing problemSpatial transcriptomics dataGlobal spatial relationshipsST data analysisTranscriptome dataUltra-large-scaleConquer strategyExpression patternsGraph networkData splittingGenes
2024
A Phase 2 study of Savolitinib in Patients with MET Amplified Metastatic Colorectal Cancer
Jia J, Moyer A, Lowe M, Bolch E, Kortmansky J, Cho M, Lenz H, Kalyan A, Niedzwiecki D, Strickler J. A Phase 2 study of Savolitinib in Patients with MET Amplified Metastatic Colorectal Cancer. Journal Of Gastrointestinal Cancer 2024, 56: 29. PMID: 39652198, PMCID: PMC11993306, DOI: 10.1007/s12029-024-01156-x.Peer-Reviewed Original ResearchMeSH KeywordsAgedColorectal NeoplasmsFemaleGene AmplificationHumansMaleMiddle AgedProtein Kinase InhibitorsProto-Oncogene Proteins c-metTriazinesConceptsTreatment-emergent adverse eventsMetastatic colorectal cancerPhase 2 studyEpidermal growth factor receptorAnti-tumor activityStable diseaseProgressive diseaseChemotherapy refractory metastatic colorectal cancerOral small-molecule tyrosine kinase inhibitorColorectal cancerResistance to epidermal growth factor receptorSmall molecule tyrosine kinase inhibitorsRefractory metastatic colorectal cancerBest overall responseRAS wild-typeAdvanced solid tumorsBiomarker-selected patientsTyrosine kinase inhibitorsWild-typeGrowth factor receptorResultsFive patientsPrimary endpointSecondary endpointsSolid tumorsSavolitinibTrajectories of Cancer Survivors' Spiritual Well‐Being Through the Transition From Treatment to Early Survivorship
Park C, Magin Z, Bellizzi K, Sanft T. Trajectories of Cancer Survivors' Spiritual Well‐Being Through the Transition From Treatment to Early Survivorship. Psycho-Oncology 2024, 33: e70040. PMID: 39632284, PMCID: PMC11793928, DOI: 10.1002/pon.70040.Peer-Reviewed Original ResearchConceptsSpiritual well-beingCancer survivorsSocial supportWell-beingModerate level of spiritual well-beingAdult cancer survivorsLevel of spiritual well-beingDiagnosis of breastYears of survivorshipHigh social supportLatent class linear mixed modelMultinomial logistic regression modelLogistic regression modelsFACIT-SpPsychosocial resourcesLinear mixed modelsEarly survivorshipAdaptive copingCoping effortsCoping strategiesActive treatmentCopingColorectal cancerCharacterize trajectoriesRegression modelsGenetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric, Version 3.2024, NCCN Clinical Practice Guidelines In Oncology.
Hodan R, Gupta S, Weiss J, Axell L, Burke C, Chen L, Chung D, Clayback K, Felder S, Foda Z, Giardiello F, Grady W, Gustafson S, Hagemann A, Hall M, Hampel H, Idos G, Joseph N, Kassem N, Katona B, Kelly K, Kieber-Emmons A, Kupfer S, Lang K, Llor X, Markowitz A, Prats M, Niell-Swiller M, Outlaw D, Pirzadeh-Miller S, Samadder N, Shibata D, Stanich P, Swanson B, Szymaniak B, Welborn J, Wiesner G, Yurgelun M, Dwyer M, Darlow S, Diwan Z. Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric, Version 3.2024, NCCN Clinical Practice Guidelines In Oncology. Journal Of The National Comprehensive Cancer Network 2024, 22: 695-711. PMID: 39689429, DOI: 10.6004/jnccn.2024.0061.Peer-Reviewed Original ResearchConceptsMultigene panel testingPathogenic/likely pathogenic variantsGenetic/Familial High-Risk AssessmentColon cancer screeningColon cancer riskHigh risk of cancerNCCN Clinical Practice GuidelinesClinical practice guidelinesRisk of cancerPanel testingHigh riskPathogenic variantsPeutz-Jeghers syndromeLynch syndromeCancer screeningDe-implementationCancer riskEndometrial cancerPTEN hamartoma tumor syndromeHigh-risk assessmentPractice guidelinesHamartoma tumor syndromePeutz-JeghersNCCN GuidelinesCHEK2The effects of a psychoeducational intervention on caregivers of colorectal cancer patients: A meta-analysis of randomized controlled trials
Zhang M, Xue Y, Shao M, Yang Y, Yu L, Ma B, Li D, Zhou H, Wang K, Chen C, Cheng M, Wang T. The effects of a psychoeducational intervention on caregivers of colorectal cancer patients: A meta-analysis of randomized controlled trials. European Journal Of Oncology Nursing 2024, 74: 102739. PMID: 39729814, DOI: 10.1016/j.ejon.2024.102739.Peer-Reviewed Original ResearchMeSH KeywordsAdaptation, PsychologicalCaregiversColorectal NeoplasmsHumansQuality of LifeRandomized Controlled Trials as TopicConceptsPsychoeducational interventionRandomized controlled trialsPsychological statusImpact of psychoeducational interventionsAspects of caregivingReduce caregiver burdenControlled trialsEnhancing caregivers' abilityCondition of caregiversImprove quality of lifeQuality of lifeCaregiver burdenCRC patientsRandom-effects modelCaregivers' abilityCINAHL CompletePerception of family supportGeneral well-beingActive lifestyleWeb of ScienceMeta-analysis of randomized controlled trialsPhysical healthCare scheduleSocial supportFixed-effects modelElectrochemotherapy in the Locoregional Treatment of Metastatic Colorectal Liver Metastases: A Systematic Review
Barbieri P, Posa A, Lancellotta V, Madoff D, Maresca A, Cornacchione P, Tagliaferri L, Iezzi R. Electrochemotherapy in the Locoregional Treatment of Metastatic Colorectal Liver Metastases: A Systematic Review. Current Oncology 2024, 31: 7403-7413. PMID: 39590176, PMCID: PMC11592455, DOI: 10.3390/curroncol31110546.Peer-Reviewed Original ResearchConceptsCRC liver metastasesLiver metastasesColorectal cancerComplete responseOverall survivalProgressive diseaseInclusion criteriaResection of CRC liver metastasesTreatment of CRC liver metastasisColorectal cancer liver metastasesSystematic searches of PubMedFrequent liver metastasesMedian overall survivalSecondary liver cancerFollow-up durationColorectal Liver MetastasesMultiple risk factorsCancer-related mortalitySearch of PubMedECT-related complicationsEvidence qualityLocoregional treatmentSurgical resectionIdentified articlesGRADE approachUsing a Bayesian analytic approach to identify county-level ecological factors associated with survival among individuals with early-onset colorectal cancer
Siddique S, Baum L, Deziel N, Kelly J, Warren J, Ma X. Using a Bayesian analytic approach to identify county-level ecological factors associated with survival among individuals with early-onset colorectal cancer. PLOS ONE 2024, 19: e0311540. PMID: 39471191, PMCID: PMC11521299, DOI: 10.1371/journal.pone.0311540.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge of OnsetBayes TheoremColorectal NeoplasmsFemaleHumansMaleMiddle AgedPrincipal Component AnalysisRisk FactorsSEER ProgramUnited StatesConceptsAge-of-onset colorectal cancerEarly-onset colorectal cancerEnd Results Program dataCenters for Disease Control and Prevention dataCounty-level factorsColorectal cancerHealth risk behaviorsIdentified principal componentsOdds of survivalPreventive servicesSurvival disparitiesLinear mixed modelsEOCRCChronic diseasesPreventive factorsUS countiesSalt Lake CountyCA residentsRisk behaviorsUnited StatesProgram dataCounty-levelOlder ageBayesian analytical approachYounger ageUSPSTF Colorectal Cancer Screening Recommendation and Uptake for Individuals Aged 45 to 49 Years
Siddique S, Wang R, Yasin F, Gaddy J, Zhang L, Gross C, Ma X. USPSTF Colorectal Cancer Screening Recommendation and Uptake for Individuals Aged 45 to 49 Years. JAMA Network Open 2024, 7: e2436358. PMID: 39361285, PMCID: PMC11450516, DOI: 10.1001/jamanetworkopen.2024.36358.Peer-Reviewed Original ResearchConceptsUS Preventive Services Task ForceUS Preventive Services Task Force recommendationsColorectal cancer screening uptakeAverage-risk individualsScreening uptakeHigher socioeconomic statusSocioeconomic statusScreening recommendationsColorectal cancerColorectal cancer screening recommendationsPreventive Services Task ForceCohort studyCancer screening recommendationsScreening uptake ratesInterrupted time series analysisLow socioeconomic statusPrivate insurance beneficiariesScreening ratesSocioeconomic disparitiesRetrospective cohort studyMain OutcomesPotential disparitiesEvaluate changesClaims dataAbsolute changeCharting the metabolic biogeography of the colorectum in cancer: challenging the right sided versus left sided classification
Jain A, Morris M, Berardi D, Arora T, Domingo-Almenara X, Paty P, Rattray N, Kerekes D, Lu L, Khan S, Johnson C. Charting the metabolic biogeography of the colorectum in cancer: challenging the right sided versus left sided classification. Molecular Cancer 2024, 23: 211. PMID: 39342363, PMCID: PMC11438248, DOI: 10.1186/s12943-024-02133-5.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkers, TumorColorectal NeoplasmsFemaleHumansMaleMetabolomeMetabolomicsMiddle AgedRectumConceptsRectal cancerNormal mucosaMetabolite abundancePatient-matched tumorTumor-specific metabolitesMetabolic heterogeneityPatient survivalRectosigmoid colonSigmoid colonAnatomic subsitePatient-matched normal mucosaTransverse colonMetabolomic profilesAscending colonCRC biomarkersMetabolome DatabaseDescending colonMetabolite changesLeft-sidedRight-sidedColorectumRisk factorsMetabolome mapCancerTumorImmune microenvironmental heterogeneity according to tumor DNA methylation phenotypes in microsatellite instability-high colorectal cancers
Kim J, Hong J, Lee J, Jung M, Choi E, Cho N, Kang G, Kim S. Immune microenvironmental heterogeneity according to tumor DNA methylation phenotypes in microsatellite instability-high colorectal cancers. Cancer Immunology, Immunotherapy 2024, 73: 215. PMID: 39235590, PMCID: PMC11377388, DOI: 10.1007/s00262-024-03805-3.Peer-Reviewed Original ResearchConceptsProgrammed death-ligand 1Tumor-infiltrating lymphocytesMicrosatellite instability-high colorectal cancerCombined positive scoreTumor proportion scoreTumor mutational burdenCD8+ tumor-infiltrating lymphocytesMicrosatellite instability-highTumor-infiltrating immune cellsCpG island methylator phenotypeColorectal cancerCIMP-high tumorsDensity of CD8+ tumor-infiltrating lymphocytesProgrammed death-ligand 1 tumor proportion scoreCIMP-highConsensus molecular subtype 1Cytolytic activity scoreWhole-slide immunohistochemistryDeath-ligand 1Tumor immune microenvironmentMethylator phenotypeMicrosatellite instability-high tumorsTumor DNA methylationDNA methylation phenotypeCpG island methylator phenotype statusMetabolic regulation of the mitochondrial immune checkpoint
Montrose D, Saha S, Galluzzi L. Metabolic regulation of the mitochondrial immune checkpoint. OncoImmunology 2024, 13: 2394247. PMID: 39206097, PMCID: PMC11352702, DOI: 10.1080/2162402x.2024.2394247.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsColorectal NeoplasmsDNA, MitochondrialHumansMembrane ProteinsMitochondriaNucleotidyltransferasesConceptsTumor-targeting immune responsesColorectal cancer cellsAnticancer immunityImmune checkpointsActivation of cGASMalignant cellsImmune responseCancer cellsDisrupt mitochondrial functionAccumulation of mitochondrial DNACytosolic accumulationMitochondrial dysfunctionMetabolic regulationMitochondrial DNAMitochondrial functionSerine resultsCellsDysfunctionTislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study
Xu X, Ai L, Hu K, Liang L, Lv M, Wang Y, Cui Y, Li W, Li Q, Yu S, Feng Y, Liu Q, Yang Y, Zhang J, Xu F, Yu Y, Liu T. Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study. Nature Communications 2024, 15: 7255. PMID: 39179622, PMCID: PMC11343749, DOI: 10.1038/s41467-024-51536-x.Peer-Reviewed Original ResearchConceptsMetastatic colorectal cancerVariant allele frequencyPhase 2 studyEpidermal growth factor receptorAdverse eventsRAS wild-type metastatic colorectal cancerRAS wt metastatic colorectal cancerSingle-arm phase 2 studyWild-type metastatic colorectal cancerColorectal cancerTreatment-related adverse eventsAnti-PD-1Disease control rateProgression-free survivalRAS wild-typeTumor immune responseCombined treatment regimenWild-typeGrowth factor receptorIrinotecan combinationOverall survivalAnti-EGFRPrimary endpointTumor DNASingle-armIL-1β mediates Candida tropicalis-induced immunosuppressive function of MDSCs to foster colorectal cancer
Zhang Z, Chen Y, Pan X, Li P, Ren Z, Wang X, Chen Y, Shen S, Wang T, Lin A. IL-1β mediates Candida tropicalis-induced immunosuppressive function of MDSCs to foster colorectal cancer. Cell Communication And Signaling 2024, 22: 408. PMID: 39164774, PMCID: PMC11337875, DOI: 10.1186/s12964-024-01771-y.Peer-Reviewed Original ResearchConceptsImmunosuppressive function of MDSCsFunction of MDSCsExpression of IL-1bImmunosuppressive functionC. tropicalisColorectal cancerIL-1BProgression of colorectal cancerAntitumor immunityNLRP3 inflammasome activationColon cancer xenograft modelTumor-infiltrating MDSCsInhibit antitumor immunityPotential immunotherapeutic strategyRegulating tumor immunityTreatment of colorectal cancerSeverity of colorectal cancerCancer xenograft modelColon cancer cell linesInflammasome activationHuman colorectal cancerNLRP3 inflammasomeIn vitro supplementationImmunotherapeutic strategiesPromote CRC progressionPre‐diagnostic plasma advanced glycation end‐products and soluble receptor for advanced glycation end‐products and mortality in colorectal cancer patients
Li J, Baker J, Aglago E, Zhao Z, Jiao L, Freisling H, Hughes D, Eriksen A, Tjønneland A, Severi G, Katzke V, Kaaks R, Schulze M, Masala G, Pala V, Pasanisi F, Tumino R, Padroni L, Vermeulen R, Gram I, Braaten T, Jakszyn P, Sánchez M, Gómez‐Gómez J, Moreno‐Iribas C, Amiano P, Papier K, Weiderpass E, Huybrechts I, Heath A, Schalkwijk C, Jenab M, Fedirko V. Pre‐diagnostic plasma advanced glycation end‐products and soluble receptor for advanced glycation end‐products and mortality in colorectal cancer patients. International Journal Of Cancer 2024, 155: 1982-1995. PMID: 39057841, DOI: 10.1002/ijc.35114.Peer-Reviewed Original ResearchConceptsAssociated with CRC-specificAdvanced glycation end productsPlasma advanced glycation end productsColorectal cancerCRC-specificOverall mortalityGlycation end productsSoluble receptorCancer patientsIntracellular signaling alterationsMultivariable-adjusted Cox proportional hazards regressionCancer and NutritionCox proportional hazards regressionEuropean Prospective InvestigationFollow-up periodColorectal cancer casesColorectal cancer patientsProportional hazards regressionUltra-performance liquid chromatography mass spectrometryColorectal cancer diagnosisEnzyme-linked immunosorbent assayColorectal cancer survivalProspective InvestigationChronic inflammationSRAGEHEARTSVG: a fast and accurate method for identifying spatially variable genes in large-scale spatial transcriptomics
Yuan X, Ma Y, Gao R, Cui S, Wang Y, Fa B, Ma S, Wei T, Ma S, Yu Z. HEARTSVG: a fast and accurate method for identifying spatially variable genes in large-scale spatial transcriptomics. Nature Communications 2024, 15: 5700. PMID: 38972896, PMCID: PMC11228050, DOI: 10.1038/s41467-024-49846-1.Peer-Reviewed Original ResearchConceptsSpatially variable genesVariable genesSpatial expression patternsSpatial transcriptomics technologiesSpatial transcriptomics researchTranscriptome researchTranscriptomic technologiesBiological functionsExpression patternsSpatial transcriptomicsGenesState-of-the-art methodsColorectal cancer dataProofreading the way: immune checkpoint inhibitors in polymerase ε/polymerase δ (POLE/POLD1)-altered colorectal cancer
Cecchini M, Sundar R. Proofreading the way: immune checkpoint inhibitors in polymerase ε/polymerase δ (POLE/POLD1)-altered colorectal cancer. Annals Of Oncology 2024, 35: 582-584. PMID: 38910015, DOI: 10.1016/j.annonc.2024.04.006.Commentaries, Editorials and Letters
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply